

Table 4: Multivariate linear regression* analysis for factors associated with visual acuity score (letters) at Year 1 among eyes with hemorrhage > 50% at baseline (N=78 with Year 1 visual acuity)

Factor	Subjects	Mean Visual Acuity Score (Standard Error)	P value
Baseline visual acuity (per letter decrease)	78	-0.76 (0.12)	<0.0001
Baseline area of choroidal neovascularization, disc areas			
<=1	38	69.8 (2.33)	0.03
>1	12	61.7 (4.19)	
Unknown	28	60.7 (2.78)	
Taking AREDS supplements			
No	24	60.1 (29.3)	0.04
Yes	54	67.5 (1.95)	
Treatment Group			
Ranibizumab monthly	20	63.8 (3.22)	0.87
Bevacizumab monthly	16	67.8 (3.59)	
Ranibizumab as needed	21	65.0 (3.14)	
Bevacizumab as needed	21	65.3 (3.11)	

*The full, initial model included baseline visual acuity, baseline area of choroidal neovascularization, taking AREDS supplements, occult neovascularization, smoking status, total retinal thickness, treatment group.